Keros Therapeutics (KROS) Receivables Refunds (2025)
Keros Therapeutics (KROS) has disclosed Receivables Refunds for 1 consecutive years, with $2.2 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Receivables Refunds changed N/A year-over-year to $2.2 million, compared with a TTM value of $2.2 million through Dec 2025, changed N/A, and an annual FY2025 reading of $2.2 million, changed N/A over the prior year.
- Receivables Refunds was $2.2 million for Q4 2025 at Keros Therapeutics.
- Across five years, Receivables Refunds topped out at $2.2 million in Q4 2025 and bottomed at $2.2 million in Q4 2025.